IEM Innovation Simplifies Risk Management for High Blood Pressure - PWV an Emerging Predictor

Food and Healthcare Press Releases Monday November 10, 2014 08:32
STOLBERG, Germany--10 Nov--PRNewswire/InfoQuest

The individual risk of stroke, kidney failure and heart attack is the decisive factor over whether to start treatment for high blood pressure or increased cholesterol. The risk can be identified at any early stage by measuring the pulse wave velocity (PWV).

IEM - based in Stolberg/Germany - will present the clinically validated PWV system, "Measuring blood pressure and PWV in one", at Medica 2014.

Scientific data shows that the PWV is an independent predictor for cardiovascular events and is significantly superior to simply evaluating traditional risk factors, e.g. increased blood pressure or cholesterol or risk assessment based on the Framingham risk score.

The basic principle of the innovative PWV test method is the combination of blood pressure measurement and pulse wave analysis. PWV is considered the gold standard in arterial stiffness evaluation. It is well known that the stiffer the arteries, the greater the risk of cardiovascular diseases.

The benefit to patients and medical practitioners is the differentiation between vascular health and cardiovascular risk. The advantage is that by measuring the upper-arm blood pressure and PWV in one, a patient can be classified into "low risk" or "very high risk". This provides to the doctor a quick and solid basis for taking a decision on treatment.

The first comprehensive validated test system with the upper-arm cuff is the Mobil-O-Graph(R), which was validated against invasive catheterisation under very strict conditions.
Visit IEM GmbH at Medica from 12th - 15th November 2014 in Hall 9, Stand C68. Have your blood pressure pulse wave analysis performed.
Contactaddress for complete article and editing
I.E.M. GmbH
Cockerillstr. 69
D-52222 Stolberg
Tel: +49-2402-95-000
Fax: +49-2402-95-00-11
Source: I.E.M. GmbH

Latest Press Release

Kemin Launches New Vision and Logo for the Future

Global ingredient manufacturer sets sights on sustainably transforming 80 percent of the world by 2042 Today Kemin Industries, a global ingredient manufacturer, unveiled its new global vision and logo to align the company strategically for 2042 and...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The...

Zeus Expands Portfolio with New Polyimide Family of Products

Products Include PI Tubing, PI Coated Wire, PI Glide(TM) Tubing, and PI Glide(TM) Coated Wire Zeus Industrial Products, Inc. (Zeus), a leading polymer solutions provider and material science innovator, has announced the introduction of a new polyimide...

SCG partners up with Frances Institut Pasteur to combat dengue with innovations to reduce mosquito breeding

Dr. Suracha Udomsak, Chief Technology Officer, on behalf of Chemicals Business, SCG, and Dr. Anavaj Sakuntabhai, Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases, representing Institut Pasteur,...

เอสซีจี จับมือ สถาบันปาสเตอร์ ฝรั่งเศส หยุดการระบาดของโรคไข้เลือดออกด้วยการพัฒนานวัตกรรมลดการแพร่พันธุ์ยุงลาย

ธุรกิจเคมิคอลส์ เอสซีจี โดย ดร.สุรชา อุดมศักดิ์ Chief Technology Officer และ สถาบันปาสเตอร์ ประเทศฝรั่งเศส (Institut Pasteur) โดย ดร. อนวัช ศกุนตาภัย Coordinator of the Defeat Dengue Program, Head of Structure, Functional Genetics of Infectious Diseases,...

Related Topics